Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
批准号:
10308238
负责人:
Arun P. Wiita
金额:
$5.53万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-01 至 2023-02-28
关键词:
Active LearningAlternative SplicingAmericanAutomobile DrivingAwardBindingBiological Response Modifier TherapyBiologyCRISPR screenCaliforniaCell physiologyCellsChemicalsChemistryChimeric ProteinsComplementComplexDataDevelopmentDiagnosisDiseaseDisease remissionDoctor of PhilosophyElementsEngineeringEssential GenesFacultyFeedbackFirst Generation College StudentsFosteringFutureGeneticGoalsGrantHIVHematopoietic NeoplasmsIn VitroLaboratoriesLatinaLos AngelesMalignant NeoplasmsMass Spectrum AnalysisMedicineMentorsMentorshipMessenger RNAMolecular MachinesMultiple MyelomaNaturePaperParentsPatientsPeptidesPharmaceutical PreparationsPhenotypePhysiologicalPlasma CellsPlayPositioning AttributePost-Translational Protein ProcessingPostdoctoral FellowProteasome InhibitorProtein EngineeringProteomeProteomicsPublishingRNA SplicingReagentRecombinant Fusion ProteinsRecombinant ProteinsRecombinantsResearchResearch TrainingResistanceResistance developmentRoleSan FranciscoScientistSeriesSpecificitySpliceosomesStudentsSystemTestingTherapeuticTrainingUniversitiesWestern BlottingWorkWritingYeastsantibody engineeringbasecancer cellcancer therapycareer developmentdesignexperienceexperimental studygenome-widegraduate studentin vitro Modelinhibitor/antagonistknock-downmRNA PrecursormRNA sequencingmid-career facultynanobodiesnovelpeerphosphoproteomicsprofessorprogramsprotein degradationproteostasisresponsesmall moleculetherapy resistanttooltranscriptome sequencingtranscriptomicsubiquitin-protein ligaseundergraduate student
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
This NCI Supplement to Promote Diversity is designed to support the career development of Ms. Audrey
Kishishita, a second year student in the Chemistry and Chemical Biology Graduate Program at the University
of California, San Francisco. Ms. Kishishita is of Latina descent and a first-generation college student who
completed her undergraduate studies with high accolades at California State University-Los Angeles. The
supplement is related to R01 CA226851, whose PI is Arun Wiita, MD, PhD. Dr. Wiita, an Associate Professor
in the Dept. of Laboratory Medicine at UCSF, will serve as Ms. Kishishita's primary mentor for this proposal.
The research plan of the Supplement directly relates to Aim 2 of the R01, which is focused on studying the role
of alternative splicing in the blood cancer multiple myeloma. Specially, a major goal of this Aim in the R01 is to
identify new ways to modulate splicing that may be beneficial either to perturb myeloma biology or potentially
as a therapeutic. Here, Ms. Kishishita proposes experiments to develop novel recombinant protein fusion
constructs that can enter myeloma cells and specifically degrade subunits of the spliceosome. She will first
work to validate the principle of these degraders using GFP as a test substrate and then move on to
engineering nanobody recognition elements for targeted splicing factors. She will further use mass
spectrometry-based proteomics and mRNA-seq to evaluate downstream effects of this degradation. To
complement the expertise of the primary mentor in myeloma biology, proteomics, splicing, and nanobody
engineering, the co-mentor, Dr. Charles Craik, is a University Professor at UCSF with a >30 year track record
of mentorship. Dr. Craik is also a leading expert in protein engineering and protein degradation, directly
relevant to the proposal here. Drs. Wiita and Craik have worked with Ms. Kishishita to craft a comprehensive
training plan including experiential learning, a series of both internal and external didactic courses,
opportunities to present scientific work to receive feedback, experience in grant- and paper-writing, and
opportunities for networking with peers and more experienced scientists. This training plan is designed to
provide Ms. Kishishita with a unique skillset and scientific experience to carry her forward into her post-doctoral
work and ultimately into an independent faculty position. We are excited to complete the proposal here to
support the career development of a scientific trainee with outstanding potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
-
批准号:10290239
-
项目类别:
-
资助金额:$20.32万
-
财政年份:2021
-
负责人:Arun P. Wiita
-
依托单位:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
-
批准号:10461112
-
项目类别:
-
资助金额:$8.08万
-
财政年份:2021
-
负责人:Arun P. Wiita
-
依托单位:
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
-
批准号:10434121
-
项目类别:
-
资助金额:$22.11万
-
财政年份:2021
-
负责人:Arun P. Wiita
-
依托单位:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
-
批准号:10286951
-
项目类别:
-
资助金额:$8.08万
-
财政年份:2021
-
负责人:Arun P. Wiita
-
依托单位:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
-
批准号:10341162
-
项目类别:
-
资助金额:$27.82万
-
财政年份:2018
-
负责人:Arun P. Wiita
-
依托单位:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
-
批准号:10524110
-
项目类别:
-
资助金额:$8.53万
-
财政年份:2018
-
负责人:Arun P. Wiita
-
依托单位:
In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometry
-
批准号:9167306
-
项目类别:
-
资助金额:$189.0万
-
财政年份:2016
-
负责人:Arun P. Wiita
-
依托单位:
Global Assessment of Myeloma Response to Chemotherapy
-
批准号:8819976
-
项目类别:
-
资助金额:$15.29万
-
财政年份:2014
-
负责人:Arun P. Wiita
-
依托单位:
Global Assessment of Myeloma Response to Chemotherapy
-
批准号:8928081
-
项目类别:
-
资助金额:$15.29万
-
财政年份:2014
-
负责人:Arun P. Wiita
-
依托单位:
Global Assessment of Myeloma Response to Chemotherapy
-
批准号:9337420
-
项目类别:
-
资助金额:$11.27万
-
财政年份:2014
-
负责人:Arun P. Wiita
-
依托单位:
海外基金